Fruquintinib Combined With Trastuzumab and XELOX as First-line Treatment in Patients With HER2-positive Advanced Gastric Cancer

Fruquintinib Combined With Trastuzumab and XELOX as First-line Treatment in Patients With HER2-positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: an Open-label, Single-arm, Single-center Phase Ib/II Clinical Study

This study was designed to evaluate the safety and efficacy of fruquintinib plus trastuzumab, and XELOX as first-line treatment for HER2-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma.

Study Overview

• Status: Recruiting
• Conditions: Gastric Adenocarcinoma; HER2-positive Gastric Cancer; Fruquintinib; Gastric (Stomach) Cancer; GEJ Adenocarcinoma; First-line Therapy
• Intervention / Treatment: Drug: fruquintinib＋trastuzumab + XELOX

• Study Type: Interventional
• Enrollment (Estimated): 45
• Phase: Phase 2; Phase 1

Contacts and Locations

• Study Contact: Name: Huifang Lv; Phone Number: 8618639027635; Email: zlyylvhf1859@zzu.edu.cn

Study Locations

• China
  • Henan
    • Zhengzhou, Henan, China, 210000
      • Recruiting
      • Henan Cancer Hospital (Affiliated Cancer Hospital of Zhengzhou University)
      • Contact: Huifang Lv; Phone Number: 18639027635; Email: zlyylvhf1859@zzu.edu.cn
      • Principal Investigator: Huifang Lv

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Have fully understood the study and voluntarily signed the informed consent;
• 18-75 years old (including 18 and 75 years old);
• Pathologically determined advanced gastric or gastroesophageal junction adenocarcinoma;
• No previous anti-tumor treatment for metastatic diseases;
• HER2 positive;
• Eastern Cooperation Oncology Group (ECOG) performance status of 0-1;
• Life expectancy ≥ 3 months;
• At least one measurable lesion according to RECIST version 1.1;

• The functions of vital organs met the following requirements (Blood components and cell growth factors were not allowed within 14 days before enrollment):

  • Absolute neutrophil count ≥1.5×109/L;
  • Platelet ≥100×109 /L;
  • Hemoglobin ≥90g/L;
  • Total bilirubin < 1.5 ULN;
  • ALT and/or AST < 1.5 ULN ;
  • Serum creatinine (Cr) <1.5×ULN;
  • Endogenous creatinine clearance ≥50ml/min;
• Female patients of childbearing age should take effective contraceptive measures;
• Good compliance, cooperate with follow-up.

Exclusion Criteria:

• Failure to comply with the study protocol or study procedure;
• Previous treatment with vascular endothelial growth factor receptor (VEGFR) inhibitors, chemotherapy or immune checkpoint inhibitors;
• Have had other malignancies within the past 5 years, except basal cell or squamous cell carcinoma of the skin after radical surgery, or carcinoma in situ of the cervix;
• Known presence of symptomatic central nervous system metastasis or brain metastases;
• Had autoimmune disease or history of autoimmune disease within 4 weeks before enrollment;
• Previously received allogeneic bone marrow transplantation or organ transplantation;
• Uncontrolled malignant ascites (defined as ascites that cannot be controlled by diuretics or puncture as determined by the researcher);
• Severe cardiovascular disease, including unstable angina pectoris or myocardial infarction, occurs within 6 months before the start of study treatment;
• Subjects who are allergic to the investigational drug or any of its adjuncts;
• Participated in other domestic unapproved or unmarketed drug clinical trials and accepted the corresponding experimental drug treatment within 4 weeks before enrollment;
• International Standardized Ratio (INR) >1.5 or partially activated prothrombin time (APTT) >1.5×ULN;
• The investigator identified clinically significant electrolyte abnormalities;
• Hypertension that could not be controlled by drugs before enrollment was defined as: systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg;
• Poorly controlled diabetes mellitus was present before enrollment (fasting glucose concentration ≥CTCAE level 2 after formal treatment);
• Had any disease or condition prior to enrollment that affected drug absorption, or the patient could not take fruquintinib orally;
• Gastrointestinal diseases such as active ulcer of stomach and duodenum, ulcerative colitis, or active bleeding of unresectosed tumors, or other conditions that may cause gastrointestinal bleeding or perforation as determined by researchers before enrollment;
• Patients with evidence or history of significant bleeding tendency within 3 months prior to enrollment (bleeding within 3 months >30 mL, hematemesis, stool, stool blood), hemoptysis (within 4 weeks >5 mL of fresh blood) or had a thromboembolic event (including stroke events and/or transient ischemic attacks) within 12 months;
• Clinically significant cardiovascular disease, including but not limited to acute myocardial infarction, severe/unstable angina pectoris, or coronary artery bypass grafting within 6 months prior to enrollment; New York Heart Association (NYHA) Grades for Congestive Heart Failure >Level 2; Ventricular arrhythmias requiring medical treatment; LVEF (Left ventricular Ejection Fraction) <50%;
• Clinically significant cardiovascular disease, including but not limited to acute myocardial infarction, severe/unstable angina pectoris, or coronary artery bypass grafting within 6 months prior to enrollment; New York Heart Association (NYHA) Grades for Congestive Heart Failure >Level 2; Ventricular arrhythmias requiring medical treatment; LVEF (Left ventricular Ejection Fraction) >50%;
• Unmitigated toxicity higher than CTCAE v5.0 grade 1 due to any previous anticancer therapy, excluding alopecia, lymphocytopenia, and oxaliplatin grade ≤2 neurotoxicity;
• Women who are pregnant (positive pregnancy test before medication) or breastfeeding;
• Received blood transfusion therapy, blood products and hematopoietic factors, such as albumin and granulocyte colony-stimulating factor (G-CSF), within 14 days before enrollment;
• Any other medical condition, clinically significant metabolic abnormality, physical abnormality or laboratory abnormality, which, in the investigator's judgment, reasonably suspects that the patient has a medical condition or condition that is not suitable for the use of the investigational drug (such as having seizures and requiring treatment), or which would affect the interpretation of the study results or place the patient at high risk；
• Urine routine indicated urinary protein ≥2+, and 24-hour urinary protein volume > 1.0g;
• Complications require long-term treatment with immunosuppressants or systemic or local use of immunosuppressive corticosteroids (> 10mg/ day prednisone or other therapeutic hormone);
• Investigators believe that the patient has any other conditions that are not suitable for participating in the study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: fruquintinib＋trastuzumab + XELOX

Drug: fruquintinib＋trastuzumab + XELOX; phase Ib: fruquintinib (3+3 dose escalation design): L1: 2 mg/d, L2: 3 mg/d, L3: 4 mg/d, qd po, D1-14, Q3W; XELOX regimen: Oxaliplatin: 130mg/m2, ivgtt 2h, D1, Q3W; Capecitabine: 1000 mg/m2, bid, D1-D14, Q3W; trastuzumab: 8 mg/kg loading dose and then 6 mg/kg maintenance dose, IV, D1, Q3W; phase II: fruquintinib: RP2D; XELOX regimen: Oxaliplatin: 130mg/m2, ivgtt 2h, D1, Q3W; Capecitabine: 1000 mg/m2, bid, D1-D14, Q3W; trastuzumab: 8 mg/kg loading dose and then 6 mg/kg maintenance dose, IV, D1, Q3W. After 6-8 cycles of combination therapy, trastuzumab plus fruquintinib plus capecitabine was given as maintenance therapy until disease progression, death or intolerable toxicity.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
PFS	PFS was defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurred first.	Up to 3 years
Recommended Phase 2 doses (RP2Ds)	To determine the recommended phase 2 dose of fruquintinib, according to the dose limiting toxicities (DLTs).	When the first cycle of treatment is completed（approximately 21 days）

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
OS	OS is defined as the time from the date of randomization to the date of death due to any cause.	Up to 3 years
ORR	ORR is defined as the percentage of patients with a best overall response of complete response (CR) or partial response (PR) per RESISTv1.1.	Up to 3 years
DCR	DCR is defined as the percentage of patients with a best overall response of confirmed complete or partial response, or stable disease (CR+ PR + SD) per RESISTv1.1.	Up to 3 years

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Exploratory endpoints	To investigate the correlations between PD-L1, CD-47B, HER2 expression and immune cell infiltration with clinical outcomes.	Up to 3 years

Collaborators and Investigators

• Sponsor: Henan Cancer Hospital
• Investigators: Principal Investigator: Huifang Lv, Henan Cancer Hospital (Affiliated Cancer Hospital of Zhengzhou University)

Publications and helpful links

Helpful Links

• Related Info

Study record dates

Study Major Dates

• Study Start (Actual): February 22, 2024
• Primary Completion (Estimated): December 31, 2025
• Study Completion (Estimated): December 31, 2026

Study Registration Dates

• First Submitted: April 11, 2025
• First Submitted That Met QC Criteria: December 30, 2025
• First Posted (Estimated): January 12, 2026

Study Record Updates

• Last Update Posted (Estimated): January 12, 2026
• Last Update Submitted That Met QC Criteria: December 30, 2025
• Last Verified: March 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neoplasms by Site; Neoplasms; Gastrointestinal Neoplasms; Digestive System Neoplasms; Digestive System Diseases; Gastrointestinal Diseases; Stomach Diseases; Stomach Neoplasms; XELOX
• Other Study ID Numbers: 2023-134-001

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No